Finley John G sold $6.6M of BX

Finley John G (Chief Legal Officer) sold 45,000 shares of Blackstone Inc. (BX) at an average of $147.11 ($146.80–$147.36, $6.62M total) across 2 trades on 2026-08-11.

Original reporting
SEC EDGAR · Finley John G
Published Aug 12, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 10:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BX
Neutral
medium confidence
Mentioned
$BX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BXNeutralLow
01

Why it matters

Traders may note the insider sale as a small sentiment datapoint, but there is no accompanying operational or financial update in the text.

02

Market read

A disclosed insider sale at about $147 per share, with no 10b5-1 plan stated, but no other new company-specific catalyst.

03

What to watch

The filing does not include motivations, option exercises, or net position changes beyond the post-transaction share count, limiting inference about BX fundamentals.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-12 after-hours; reflects 2026-08-11 sale

Background

The article is a SEC Form 4 insider transaction disclosure for Blackstone Inc., reported by Chief Legal Officer Finley John G.

Company-level read

Ticker impact

$BXNeutralMedium confidence
Context

Blackstone insider Finley John G sold about 45,000 shares in open-market transactions at roughly $147.11 weighted average, per Form 4.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction, not earnings, guidance, or a corporate action. The article provides sale size and price range but no accompanying rationale or new business development.

Market effects

Minimal. Insider selling in a large asset manager is not a sector-level catalyst by itself.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be misread as bearish, but insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs not reflected here.

Key entities

  • Blackstone Inc.

    Subject of the Form 4 insider sale disclosure (BX).

  • Finley John G

    Chief Legal Officer who sold shares via open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BXMedAI 8/10

Blackstone Life Sciences announces $455M collaboration with Boston Scientific

Blackstone Life Sciences (BX) and Boston Scientific (BSX) are collaborating on a $455M project to develop the VITALYST heart pump system. This is the first co-funding deal between the two companies. The system aims to treat acute myocardial infarction cardiogenic shock by improving blood flow. BXLS sees potential in the technology to enhance current mechanical circulatory support devices.